Shopping Cart
- Remove All
- Your shopping cart is currently empty
YJ1206 is a selective CDK12/CDK13 PROTAC degrader with oral activity, demonstrating an IC50 of 12.55 nM in VCaP cells. It enhances DNA damage, induces apoptosis, and promotes tumor regression in a castration-resistant prostate cancer PDX (patient-derived xenograft) mouse model derived from original site WA74. Additionally, YJ1206 acts synergistically with AKT pathway inhibitors to suppress in vivo tumor growth.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | YJ1206 is a selective CDK12/CDK13 PROTAC degrader with oral activity, demonstrating an IC50 of 12.55 nM in VCaP cells. It enhances DNA damage, induces apoptosis, and promotes tumor regression in a castration-resistant prostate cancer PDX (patient-derived xenograft) mouse model derived from original site WA74. Additionally, YJ1206 acts synergistically with AKT pathway inhibitors to suppress in vivo tumor growth. |
Molecular Weight | 894.01 |
Formula | C49H52FN11O5 |
Cas No. | 3053716-98-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.